Some Medicare Drug Plans Are Reclassifying Common Prescriptions

Image Source: Pexels

As the 2026 plan year gets underway, many Medicare beneficiaries are discovering a quiet but significant shift at the pharmacy counter. While much of the national conversation has focused on the new $2,100 out-of-pocket cap for prescription drugs, the “fine print” of how plans are managing this change is beginning to surface. To offset the financial pressure of the new spending limits, several major Part D and Medicare Advantage insurers are reclassifying common medications. This often involves moving a drug from a “preferred” tier with a flat co-pay to a “non-preferred” tier that requires a higher percentage of coinsurance. For those on a fixed income, these administrative maneuvers can turn a formerly affordable prescription into a monthly financial hurdle. Here is what you need to know about Medicare drug reclassification.

The Financial “Push and Pull” of the $2,100 Cap

The primary reason for these reclassifications is the mandatory $2,100 annual out-of-pocket cap established by the Inflation Reduction Act. While this cap provides an essential safety net for those with chronic, high-cost conditions, it also shifts more of the financial liability onto the insurance companies themselves.

According to reports from KFF, insurers are responding by tightening their formularies to maintain profitability under these new constraints. By reclassifying certain brand-name drugs as “non-formulary” or shifting them to higher tiers, plans can steer patients toward cheaper generics or biosimilars. This “push and pull” effectively changes the cost-sharing structure for millions of Americans who may not have changed their medications in years.

Negotiated Prices and the Tier Shuffle

2026 marks the first year that Medicare’s negotiated prices for ten high-cost drugs—including Eliquis, Jardiance, and Januvia—actually take effect. While AARP notes that these negotiated prices should save beneficiaries about $1.5 billion collectively, the “tier shuffle” can complicate those savings. Some plans are reclassifying these negotiated drugs into specific “negotiated tiers” with unique coinsurance rates that may differ from your previous plan structure.

If your plan has moved your maintenance medication from Tier 2 to Tier 3, you might find that you reach your deductible faster, even if the drug’s base price is lower. This makes it more critical than ever to review your “Evidence of Coverage” document to see exactly where your specific drugs now sit.

The Surge in “Coinsurance” over “Co-pays”

A growing trend in 2026 is the replacement of predictable flat-fee co-pays with percentage-based coinsurance, especially for Tiers 3 and 4. Major providers like UnitedHealthcare have signaled that more drugs are being moved into coinsurance categories to help manage the increased costs of the Part D redesign. For a patient, this means instead of paying a steady $35 every month, you might pay 25% of the drug’s total cost, which can fluctuate based on pharmacy pricing.

This shift makes monthly budgeting significantly more difficult, as the “price” of your medicine could change with every refill until you hit the $2,100 cap. The reclassification from a co-pay tier to a coinsurance tier is often the biggest contributor to the “sticker shock” seniors are currently experiencing.

Biosimilars and the Removal of “Gold Standard” Brands

In 2026, we are also seeing an aggressive reclassification of specialty biologics, such as Humira, in favor of newly available biosimilars. Many Wellcare and Cigna plans have removed certain “gold standard” brands from their formularies entirely, replacing them with lower-cost alternatives that have the same therapeutic effect.

While biosimilars are clinically validated, the transition often requires a new prior authorization or a conversation with your doctor about switching formulas. If you insist on staying with the brand-name version, your plan may reclassify it as “non-covered,” meaning every dollar you spend on it would not count toward your $2,100 cap. This “all-or-nothing” coverage model is a new reality for many patients navigating the 2026 landscape.

Navigating the 2026 Formulary Maze

Dealing with a drug reclassification requires a proactive approach and a willingness to have difficult conversations with your medical team. If your drug has been moved to a higher tier or dropped entirely, ask your doctor about a “tiering exception” or if a clinically equivalent generic is available. Because these changes happen at the start of the year, it is vital to audit your first few pharmacy receipts of 2026 to ensure you aren’t being overcharged due to a coding error. Understanding that your “old” plan has new rules is the best way to stay ahead of the curve and protect your retirement savings. Don’t let a “tier shuffle” catch you off guard when you’re standing at the pharmacy window.

Is your favorite prescription still covered at the same price? Let us know what changes you’ve seen in the comments.